PRA Adds Large Molecule Capabilities to US Laboratory
PRA announced the addition of capabilities and services to its Lenexa, KS location.
PRA, a clinical research organization, announced the addition of capabilities and services to its Lenexa, KS location. Now, in addition to the laboratory in Assen, The Netherlands offering full-service bioanalytical capabilities, the Lenexa, KS laboratory will now offer immunochemistry services. The additions solidify PRA as the only company in the world with full-service bioanalytical capabilities near its clinics to support rapid results from Phase I clinical studies in the US and Europe.
Read the full release here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.
